# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001753926-25-001827
Filing Date
2025-11-25
Accepted
2025-11-25 08:30:42
Documents
5
Period of Report
2025-12-17

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | g085027_def14a.htm | DEF 14A | 581980
2 | GRAPHIC | img001_v1.jpg | GRAPHIC | 36006
3 | GRAPHIC | img002_v1.jpg | GRAPHIC | 36006
4 | GRAPHIC | img003_v1.jpg | GRAPHIC | 223470
5 | GRAPHIC | img004_v1.jpg | GRAPHIC | 306668
| Complete submission text file | 0001753926-25-001827.txt |  | 1413175

Mailing Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703
Business Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703 919-908-2422
Pelthos Therapeutics Inc. (Filer) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41964 | Film No.: 251515307
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)